Taysha Gene Therapies, Inc. (TSHA) stock
TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.00−0.06 (-1.48%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Taysha Gene Therapies enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Taysha Gene Therapies's enterprise value was $986.15M on Nov 11, 2026, against $1.05B a year earlier. Over the last 5 years it ranged from -$927.18K to $1.73B, with a median of $269.87M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $986.15M | -21.7% |
| 2025 | Dec 31, 2025 | $1.26B | +425.4% |
| 2024 | Dec 31, 2024 | $239.83M | +16.9% |
| 2023 | Dec 29, 2023 | $205.19M | +112.6% |
| 2022 | Dec 30, 2022 | $96.52M | -66.4% |
| 2021 | Dec 31, 2021 | $287.25M | -60.3% |
| 2020 | Dec 31, 2020 | $723.55M | – |
See a number that looks wrong?